Abstract | INTRODUCTION: MATERIALS AND METHODS: RESULTS: Altogether, 14 patients received the study drug. The blood glucose did not markedly change from baseline at major assessment points in the meal tolerance test, and a decrease in blood glucose was observed at several other assessment points. Adverse events were reported in 42.9% (6/14) of patients, but all adverse events were mild or moderate in severity, and most were not related to the study drug. No cases of death, serious adverse events or hypoglycemia were reported. DISCUSSION:
|
Authors | Nobuya Inagaki, Hiroki Sano, Yoshifumi Seki, Shingo Kuroda, Kohei Kaku |
Journal | Journal of diabetes investigation
(J Diabetes Investig)
Vol. 9
Issue 2
Pg. 354-359
(Mar 2018)
ISSN: 2040-1124 [Electronic] Japan |
PMID | 28836351
(Publication Type: Clinical Trial, Phase III, Journal Article)
|
Copyright | © 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. |
Chemical References |
- Blood Glucose
- Dipeptidyl-Peptidase IV Inhibitors
- Glycated Hemoglobin A
- hemoglobin A1c protein, human
- Uracil
- trelagliptin
|
Topics |
- Aged
- Blood Glucose
(analysis)
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(adverse effects, therapeutic use)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Uracil
(adverse effects, analogs & derivatives, therapeutic use)
|